LexaGene Starts the Year with Additional MiQLab Sales
03. Januar 2022 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that has commercialized an instrument for...
LexaGene Announces Results of Annual General and Special Meeting
17. Dezember 2021 13:08 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that has commercialized an instrument for...
LexaGene Closes Multiple MiQLab Sales
03. Dezember 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen...
LexaGene Intends to Pursue Full Panel Pathogen Testing through the FDA
24. November 2021 16:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...
Leading Veterinary Academic, Dr. Jane Sykes, Joins LexaGene Board of Directors
15. November 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...
LexaGene Expands Bio-Pharma Contamination Panel by Adding Test that includes a Biothreat Agent
09. November 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene”), a molecular diagnostics company that has commercialized an instrument for...
LexaGene Receives 2021 BioTech Breakthrough Award
02. November 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...
LexaGene Finalizes Design of Pneumonia Panel
01. November 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...
LexaGene Completes First Stage of U.S. ARMY DEVCOM Agreement
29. Oktober 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Oct. 29, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...
LexaGene’s MiQLab™ System Selected to be a Best in Show Spotlight at the 47th Annual Industry Petcare Innovation Summit
27. Oktober 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...